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Abstract 
The new multimodality cardiovascular imaging journal, European Heart 
Journal – Cardiovascular Imaging, was created in 2012. It has already gained an 
impressive impact factor of 3.669 during its 2 first years. In two articles we will 
summarize the most important studies from the journal’s third year. Part I of the 
review will focus on studies in myocardial function, myocardial ischaemia, and 
emerging techniques in cardiovascular imaging, and Part II will focus on valvular 
heart diseases, heart failure, cardiomyopathies, and congenital heart diseases. 
  
 The multimodality European Heart Journal – Cardiovascular Imaging has 
successfully transitioned from an exclusive echocardiographic journal 3 years ago. 
The journal now serves as an important resource for general cardiologists, specialists 
in all imaging modalities, and other physicians working in the field of cardiovascular 
imaging. The tradition of highlighting the most important studies that were published 
in the last year editions is continued (1–3). In two articles we will summarize the most 
important papers from the journal in 2014. Part I is focused on studies in myocardial 
function, myocardial ischaemia, and emerging techniques in cardiovascular imaging. 
Recommendations from the European Association of Cardiovascular 
Imaging 
The main task of European Heart Journal – Cardiovascular Imaging is to 
publish scientific articles. Another important assignment for the journal is to publish 
position papers, recommendations and expert consensus papers from the European 
Association of Cardiovascular Imaging (EACVI). The journal published three 
recommendations in the field of multimodality imaging (4–6).  
Cancer therapeutics have for long time been known to potentially cause 
Cancer therapeutics–related cardiac dysfunction (CTRCD). The EACVI and the 
American Society of Echocardiography (ASE) have published for the first time in 
2014 an expert consensus article about multimodality imaging evaluation of adult 
patients during and after cancer therapy(6). A position paper on multimodality 
imaging in pericardial diseases highlighted the respective role of each technique 
according to the clinical context in the diagnosis and management of pericardial 
diseases(5). A dedicated Taskforce has been appointed by the European Society of 
Cardiology (ESC) and the EACVI to develop appropriateness criteria for 
cardiovascular imaging use in clinical practice in Europe, (4). The published paper in 
2014 described the development process of these appropriateness criteria in 
Europe(7).  
In 2014, the EACVI has also published three recommendation articles on 
echocardiographic topics (8–10). The collection of echocardiographic 
recommendation papers published in 2014 consists of an update of the use 
transoesophageal echocardiography (TOE) with particular focus on areas of 
interventional TOE, including transcatheter aortic, mitral, and left atrial appendage 
interventions, as well as on the role of TOE in infective endocarditis, adult congenital 
heart disease, and aortic disease(8). One article addressed the EACVI´s viewpoint on 
the concept of point-of-care, problem-oriented focus cardiac ultrasound examination 
(FoCUS)(9). The last echocardiographic paper updated the EACVI standards and 
processes for accreditation of echocardiographic laboratories(10). 
The official EACVI Core Syllabus for the European Cardiovascular Magnetic 
Resonance Certification Exam was also published in 2014(11).  
A highly valued editorial written by the deceased former editor-in-chief of the 
European Journal of Echocardiography, Professor Jos R.T.C. Roelandt, asked if 
echocardiography was to blame for the decline of our physical examination skills(12). 
He concluded that future generations of doctors would find it hard to believe that, in 
2013, many clinicians were still relying on the vague findings of a 200-year-old 
traditional physical examination and were compromising clinical efficacy when direct 
information was available from point-of-care echocardiography. History will 
undoubtedly show that point-of-care echocardiography is the beginning of a ‘new 
glorious age’ of the physical examination 
 Myocardial function 
During the last 2 years a significant number of articles has been published, 
which described the normal reference ranges for echocardiographic studies(13–17). 
We might wonder why all these reports are necessary, but the definition of normal 
ranges differ according to age, gender, body surface area, and ethnicity(18). Newer 
ultrasound techniques also affect our measurements. Large studies on normal ranges 
in different types of patients are therefore welcome and will be critical to make 
correct diagnostic conclusions in our patients. 
Assessment of myocardial function has always been one of the most important 
goals of every cardiac imaging study in most patients. Left ventricular ejection 
fraction (LVEF) has traditionally been the single most important parameter of LV 
performance, but a lot of newer and important echocardiographic parameters are now 
into clinical use. Assessment of LV longitudinal function has been demonstrated to 
give incremental and additional information to LVEF and can, for example, be done 
by the evaluationmitral annular displacement (MAD). MAD can be calculated from 
M-mode, colour tissue Doppler imaging (TDI), and two-dimensional (2D) strain 
echocardiography. The article from de Knegt et al. has tested the agreement and 
reproducibility of MAD assessed by these various echocardiographic modalities(19). 
They found that MAD could be assessed by all three methods, but they were not 
interchangeable. Figure 1 shows the different echocardiographic methods to assess 
LV systolic function by MAD.  
Questions remain about the variability among different vendors about strain 
values and tissue velocity measurements. An EACVI driven initiative aims to get the 
vendors and experts together in order to standardize the way the assessments are 
done(20). Another interesting study from Dhutia et al. presented differences and a 
simple method for calibrating tissue Doppler velocity measurements to make them 
more consistent (21,22).  
Assessment of all chamber function by speckle tracking echocardiography 
(STE) has been included in many echocardiographic laboratories in the recent years. 
The 2D technique has been accepted to give additional and superior information to 
assessment of LVEF alone. A number of reports about 3D strain have also been 
published the last years, but so far the results are discordant with regards to 
superiority of the 2D method (23). A recent report by Altman et al. concluded that 3D 
STE allowed accurate and faster analysis of deformation when compared with 2D 
STE and might represent a viable alternative in the evaluation of global LV 
function(24). They studied 166 patients with different types of pathology and found 
that area strain and longitudinal strain from the 3D technique was best, but that further 
improvements were needed to firmly establish this technology as superior to 2D in the 
assessment of deformation. 
A multicentre study from USA and Australia tested the ability of global 
longitudinal strain (GLS) to identify systolic dysfunction in 159 patients receiving 
anthracyclines, trastuzumab and or not cardioprotective beta-blockers(25). Their 
results showed that GLS could be used to document impairment of cardiac function in 
patients treated with anthracyclines, trastuzumab, or both. In addition, this was the 
first study to evaluate the echocardiographic (strain and LVEF) responses to treatment 
initiated in response to a reduction in myocardial deformation engendered by 
chemotherapy-induced cardiotoxicity. Their results suggested that beta-blocker 
therapy might facilitate the recovery of cardiotoxicity. 
Studies by STE has revealed LV dysfunction in many groups of patients in 
whom LVEF remain normal. Roos et al. studied 112 asymptomatic patients with type 
2 diabetes mellitus with an interval of 2 years(26). They had normal LVEF and were 
53±10 years (59% men) at inclusion. The patients remained clinically stable between 
baseline and follow-up echocardiography. After 2-year follow-up, the authors found a 
significant increase in the LV mass index and LVEF remained unchanged. In contrast, 
the article showed a significant impairment in circumferential and longitudinal strain. 
The authors concluded that also asymptomatic patients with type 2 diabetes mellitus 
and apparently normal LVEF might show mild progression of subclinical LV function 
assessed with 2D STE.  
One substudy from the Coronary Artery Risk Development in Young Adults 
(CARDIA) investigated whether the addition of left atrial (LA) size determined by 
echocardiography improved cardiovascular risk prediction in 4082 young adults over 
and above the clinically established Framingham 10-year global CV risk score 
(FRS)(27). LA size was assessed from M-mode. LA diameter and 2D 4-chamber LA 
area were then indexed by height or body surface area (BSA). The authors concluded 
that LA size measurements independently predicted clinical outcomes. However, it 
only improved discrimination over clinical parameters modestly without altering risk 
classification. The CARDIA study used more than 20 years old echocardiographic 
studies and the technique has been improved significantly since that. LA size can now 
be assessed by 3D wall motion tracking, and de Isla et al. concluded that these 
measurements compared well with cardiac magnetic resonance (CMR)(28). In 
addition, they concluded that the method was fast, accurate, and reproducible, and it 
allowed a better classification of LA enlargement severity compared with 2D echo. 
The LA size has also been related to the success of radiofrequency catheter 
ablation (RFCA) for atrial fibrillation (AF), but potential predictors after a repeated 
procedure are still unknown. The study from Montserrat et al. checked if a 
combination of LA analysis with 3D echo and clinical data predicted elimination of 
AF after a first ablation procedure for AF, beyond LA size(29). They showed that 
although larger LA size was moderately associated with worse success rates of RFCA 
in patients with AF, the analysis of LA function by 3D echocardiography added an 
independent predictive value to identify candidates for successful ablation. LA 
expansion index, which is a ratio of maximum and minimum volumes, was one of the 
best parameters to predict successful therapy. 
The value of assessing E/e´ ratio for estimation of LV filling pressures is 
debated. The design of a new large EACVI initiated European study that compares 
invasive pressures to E/e´ is described in the last year of the journal(30). The EURO-
FILLING study will be performed at leading European centres and is expected to 
provide important information on non-invasive assessment of LV filling pressure and 
to contribute to the standardization of this assessment in clinical practice. 
Obesity has significant impact on morbidity and mortality. The paper from 
Kaier et al. reported, for the first time, that bariatric surgery has favorable cardiac 
effects in these patients(31). Both LV and right ventricular (RV) function six months 
past surgery showed evidence of improvement by 3D echocardiography. There were 
no differences with regards to ventricular remodeling when comparing sleeve 
gastrectomy and gastric bypass. 
Myocardial ischaemia 
Ischaemic myocardium often stretches, before it contracts, in early systole 
when the intraventricular pressure rises steeply during the isovolemic contraction 
phase(32). This stretch can easily be identified by strain through the speckle tracking 
technique. Zahid et al. found that the duration of this early stretch could identify 
coronary occlusion and even patients with minimal myocardial damage.  
The assessment of coronary flow velocity reserve (CFVR) by Doppler is a 
promising non-invasive method for detecting myocardial ischaemia. However, the 
relationship to fractional flow reserve (FFR) was unknown before the study from 
Wada et al. was published(33). The study showed closes relationships between the 
two methods and thus encouraged the hope for the Doppler method.  
The detection of coronary atherosclerosis for the detection of subclinical 
coronary artery disease (CAD) remains challenging. Coronary lumen integrity is of 
limited value, and intravascular ultrasound is an invasive method to assess vessel wall 
remodelling and characterization of plaque composition. Jahnke et al. tested a 
comprehensive CMR imaging protocol (3D vessel wall imaging and flow 
measurement of the proximal right coronary artery, myocardial T2*, and first-pass 
perfusion imaging) demonstrating a non-invasive approach for direct assessment of 
coronary vessel wall remodelling(34). 
The non-invasive detection of inducible myocardial ischaemia in patients with 
angiographic 3-vessel disease remains challenging. Motwani et al. demonstrated that 
in patients with angiographic 3-vessel disease, the ischaemic burden detected by 
perfusion CMR is greater with high-resolution acquisition (1.6 mm in-plane) 
compared to standard-resolution (2.5 mm in-plane), due to better detection of 
subendocardial ischaemia. High-resolution perfusion CMR may therefore be preferred 
for risk stratification and management of this high-risk patient group(35). 
Recent studies have demonstrated that chronic obstructive pulmonary disease 
(COPD) is associated with cardiovascular disease. However, the association between 
COPD and coronary microcirculatory dysfunction is unknown. Nakamori et al. 
showed that myocardial perfusion reserve (MPR) by quantitative myocardial 
perfusion CMR was impaired in patients with COPD, and independently associated 
with systemic inflammation and airflow limitation(36). 
Vasodilator stress agents un-selectively bind to adenosine receptors (A1, A2A, 
A2B, and A3), which are located in multiple tissue types. Regadenoson is a new stress 
agent with higher selectively for the A2A receptors than adenosine, with potentially 
reduced side effects. In nuclear imaging trials, regadenoson has been shown to be 
safe, non-inferior to adenosine and with fewer side effects. Nguyen et al. 
demonstrated that regadenoson CMR is also well tolerated and can be performed 
safely with a few adverse events(37). 
Infarct size, traditionally measured by Tc99m-Sestamibi Single-photon 
emission computed tomography (SPECT), is an important predictor of cardiac risk 
after acute myocardial infarction (AMI). In patients with AMI, CMR can also assess 
the presence and extent of infarct size, as well as of microvascular obstruction 
(MVO). Hadamitzky et al. demonstrated that the extent of MVO and infarct size by 
CMR have an excellent prognostic value in predicting cardiac events following AMI 
and may be used as an alternative to infarct size assessment by Tc99m-Sestamibi-
SPECT(38). They also observed that when analysing the images with 6 standard 
deviation signal intensity thresholds, infarct size by CMR had a stronger relationship 
with clinical outcomes compared with infarct size by other CMR methods or SPECT. 
Cardiac computed tomography (CT) offers useful information for risk 
stratification through the detection of obstructive CAD as well as the extent and 
distribution of non-obstructive atherosclerosis. A study compared the prognostic 
value of coronary calcium imaging and coronary CTA findings, including stenosis 
severity, extent and distribution in 8627 symptomatic patients with suspected CAD 
who had both coronary calcium imaging and coronary CTA (39). Coronary CTA 
findings add incremental discriminatory value over coronary artery calcium imaging 
for the identification of individuals at high risk of death or MI. The presence of either 
obstructive or non-obstructive CAD by coronary CTA had independent predictive 
value for the risk of major adverse cardiac events, including death, MI and late 
revascularization in 15187 individuals without previously known CAD (40). The 
large patient population allowed stratification of risk associated with CTA findings in 
different age groups. When stratified by age, individuals ≥ 65 years experienced 
higher event risk for non-obstructive, one- and 2-vessel disease than younger 
individuals. Normal CTA was associated with low risk irrespective of age.  
Morphological characteristics, such as positive remodelling, low attenuation 
or ring-like sign have been associated with coronary atherosclerotic plaques that are at 
high risk of rupture and subsequent acute coronary syndrome. One study evaluated 
the prognostic value of these vulnerable plaque features by coronary CTA in 543 
cardiac stable patients with normal SPECT perfusion study(41). Approximately one 
third of patients had high-risk plaque features that were a strong predictor (HR 9.4) of 
cardiac death, acute coronary syndrome or late revascularization. Interestingly, 
another study showed that individuals with non-calcified atherosclerotic plaques 
corresponding to the low attenuation plaques by CTA had distinct features in their 
plasma lipid profile by lipidomic analysis (42). Patients with recent acute coronary 
syndrome (ACS) present a particularly high-risk group as shown in another study 
demonstrating that almost one quartile of patients with an ACS will have new major 
cardiovascular event (cardiac death, acute coronary syndrome or late 
revascularization) unrelated to the initial culprit plaque during 5 years of follow-
up(43).  
CTA is an accurate noninvasive method for the detection of and especially 
ruling out obstructive CAD in appropriately selected patients. A systematic meta-
analysis compared the up-front diagnostic use of coronary CTA vs. exercise ECG or 
SPECT perfusion imaging based strategies(44). The diagnostic accuracy of CTA 
based strategy is higher than that of ECG or SPECT. However, coronary CTA based 
strategy results in higher number of downstream test utilization and higher number of 
revascularizations. Yerramaso et al. prospectively tested the use of coronary artery 
calcium imaging by unenhanced CT alone as an initial diagnostic test for patients in 
300 consecutive patients with stable chest pain syndrome (45). Notably, none of the 
57 patients with both low pre-test probability of CAD and zero calcium score had 
obstructive CAD or suffered a cardiovascular event during the follow-up of 17 
months. 
One possible explanation to this is that the anatomical criteria for evaluating 
haemodynamic significance of intermediate coronary artery stenosis may differ 
between non-invasive and invasive methods. In a study of 181 intermediate coronary 
lesions, it was shown that compared with invasive angiography or intravascular 
ultrasound (IVUS), coronary CTA overestimated lesion severity (minimal lumen 
diameter or minimal lumen area) and hence had lower diagnostic performance in the 
detection of haemodynamically significant stenosis defined as FFR value ≤ 0.8 (40) 
Layniz et al. studied diagnostic accuracy of very low-dose (on average 0.6 mSv) 
coronary CTA in patients with suspected CAD. Although iterative reconstruction 
algorithm reduced image noise, it did not improve diagnostic accuracy over standard 
filtered back projection algorithm in this study (46). 
Epicardial adipose tissue (EAT) can be measured from cardiac CT-scans. Tran 
et al. showed that a practical EAT measurement in a single axial slice at the level of 
the left main coronary artery ostium correlated well with the measurement of total 
EAT from the same non-contrast CT scan and was associated with the presence of 
obstructive CAD (47). Mahabadi et al. studied CT scans of 3467 participants of the 
Neinz Nixdorff Recall–study and found that the left atrial size on CT scans is a strong 
predictor of incident AF, whereas EAT did not improve prediction of AF over LA 
size or traditional risk factors(48). 
The current trends in nuclear perfusion imaging include the use of novel rapid 
SPECT scanners and the growing use of PET and quantitation. Joutsiniemi et al. 
investigated whether absolute stress flow alone is sufficient in detecting CAD(49). 
The authors found that absolute stress perfusion alone was superior to perfusion 
reserve in the detection of haemodynamically significant CAD. This allows shorter 
stress-only imaging protocols with smaller radiation dose as it has been suggested for 
SPECT. In a multi-centre registry study of 953 patients with previous CABG, Rb-82 
positron emission tomography (PET) perfusion imaging provided independent and 
incremental prognostic value to clinical variables for both all-cause mortality and 
cardiac death(50).  
Another trend is to use hybrid imaging. Kim et al. found that sequential 
imaging of SPECT and CTA has incremental prognostic value in patients with 
suspected CAD(51). Correspondingly, Schaap at al. (52) showed that hybrid 
SPECT/CTA imaging has a substantially higher yield than standalone SPECT or CTA 
in the diagnostic workup of patients suspected of significant CAD. Furthermore, 
Danad et al. found that cardiac hybrid PET/CT imaging had clear impact on 
downstream referral for invasive coronary angiography and revascularization(53). 
Especially with an equivocal CT study myocardial perfusion imaging had clear 
impact on referral rates for ICA and revascularization. 
Molecular imaging 
The most common molecular imaging tracer for cardiac diseases is 18F-FDG. 
Asmar et al. assessed the clinical importance of 18F-FDG PET/CT in the extra-
cardiac findings in 72 patients with infective endocarditis(54). PET/CT detected 114 
lesions and 64 were true positive, of which 25 were new findings and detected in 17 
patients. In 11 patients, the lesions were considered to have a clinical importance. 
Thus, 18F-FDG imaging may have impact not only for cardiac diagnosis of 
endocarditis but also in detecting peripheral infection foci in these patients. 
Innervation imaging using myocardial 123I-MIBG scintigraphy has been 
shown to have prognostic value in patients with chronic heart failure. In a pooled 
individual patient data meta-analysis of 636 patients the late heart to mediastinum 
(H/M) ratios were compared against the incidence of all-cause mortality, cardiac 
mortality, arrhythmic events, and heart transplantation. In multivariate analysis, late 
H/M was an independent predictor for all event categories, except for 
arrhythmias(55).  
99mTc-DPD is better known as bone scintigraphy tracer. Hutt et al 
investigated the potential of 99mTc-DPD scintigraphy in 321 patients with suspected 
cardiac amyloidosis(56). 99mTc-DPD was very sensitive method for imaging cardiac 
transthyretin (ATTR) amyloid. The authors found that 99mTc-DPD scintigraphy is a 
sensitive technique for imaging cardiac amyloidosis but further studies are warranted 
to understand better the behaviour of the tracer in different subtypes of amyloidosis.  
Emerging techniques in cardiovascular imaging 
Myocardial parametric mapping, namely native T1 and extracellular volume 
fraction (ECV, derived from T1 mapping pre and post contrast), are new cardiac MRI 
methods that have brought a new dimension to non-invasive myocardial tissue 
characterization. Whilst alteration in native T1 may result from processes affecting 
the myocardium, the interstitium, or both, ECV mapping specifically quantifies 
expansion of the interstitial space. 
H-Ici reviews the role of T1 mapping in both acute and chronic myocardial 
infarction, an unprecedented opportunity to non-invasively quantify changes in the 
myocardial structure and interstitial compartment, with the potential to provide 
incremental information over late gadolinium enhancement imaging for the diagnosis 
and treatment of patients with ischaemic heart disease. 
T2 mapping is also a new parametric imaging technique aiming at improving 
the detection of myocardial oedema, traditionally performed with the standard T2-
weighted imaging. In the context of acute myocardial infarction, the oedematous area 
corresponds to the area at risk (AAR), which includes the infarcted area (detectable 
by late gadolinium enhancement imaging) and the salvaged myocardium. The study 
by Hammer-Hansen uses quantitative T2 maps to characterize and quantify the 
salvaged and infarcted myocardium within the AAR in a dog model of reperfused 
acute myocardial infarction(57). They demonstrated that differences in the T2 of 
infarcted and salvaged myocardium vs. remote myocardium were apparent after both 
4 and 48 h of reperfusion. They also reported that reperfusion time seems to have an 
impact on the magnitude of the T2 abnormality in the salvaged area, decreasing 
substantially already in the early phases of healing. Further studies are warranted to 
determine the optimal timing for AAR imaging and progression of T2 abnormalities. 
Oxygenation-sensitive cardiovascular magnetic resonance (OS-CMR) imaging 
is a potential interesting new technique to explore the impact of the functional 
severity of coronary artery stenosis on changes in myocardial oxygenation during 
pharmacological vasodilation. Luu et al. demonstrated that an invasive fractional flow 
reserve (FFR) of 0.80 is associated with a lack of an adenosine-inducible increase in 
oxygenation of the dependent coronary territory, while a complete lack of such an 
increase was best predicted by an FFR of 0.54(58). 
Further studies are warranted to identify clinically meaningful cut-off values 
for FFR measurements and to assess the utility of OS-CMR as an alternative clinical 
tool for assessing the functional relevance of coronary artery stenosis. 
A steadily increasing use of imaging methods in cardiology is produced by 
invasive methods like intravascular ultrasound (IVUS)(59,60), optical coherence 
tomography (OCT) and recently serial optical frequency domain imaging (OFDI)(61). 
OCT has in a short time become a useful tool for invasive cardiologists(62). The 
visual impression is obvious, but scientific studies will have to show the objective 
usefulness of this method. Our journal presented last year several studies that 
confirmed the exciting opportunities by OCT(63–66).  
Dauwe et al. studied a new software capable of fusing pre-procedural 
multimodal imaging of the heart with peri-procedural 3D rotational angiography 
during catheter intervention(67). In an experimental study in pigs, it was shown that 
the new software could help to guide endomyocardial injections into the infarct 
border zone area that is the target. This technology may have important implications 
for gene therapy trials. 
In two studies the new cadmium–zinc–telluride SPECT camera was tested. In 
a study by Gimelli et al. the relationships between regional adrenergic innervation 
heterogeneity, myocardial perfusion, and contractile function obtained by means of a 
low-dose imaging protocol with this novel camera was investigated in 28 patients(68). 
In another study by the same team left ventricular diastolic function was measured 
and found that LV filling dynamics correlated well with echocardiographic 
parameters of diastolic function(69). Chowdhury et al. found reliable prognostic and 
diagnostic information with this new type of camera(70). These studies indicate that 
the novel SPECT scanner technology will further improve the versatility of SPECT 
while significantly reducing image acquisition time and/or radiation dose for the 
patients. 
Figure legends: 
Figure 1 (A) Lateral mitral annuls displacement (MAD) using conventional 
M-mode measured in the four-chamber view. (B) By placing the M-mode cursor at 
the lateral border in the mitral annuls plane, an image of lateral MAD was obtained. 
The total MAD was measured from the lowest to the highest point of contraction, 
excluding post-systolic contractions (between AVO and AVC times, respectively). 
(C) Systolic velocity was determined by measuring the gradient between the 
highest and lowest points. (D) Sample areas used to determine lateral MAD by colour 
TDI were placed in the lateral basal segment just proximal to the mitral annulus. (E) 
Integration of colour TDI velocity curves allowed for the assessment of systolic 
longitudinal displacement. Post-systolic contraction was not included in total MA 
displacement measurements. (F) The determination of left ventricular longitudinal 
velocity (s′) in the lateral wall in the apical four-chamber view. (G) 2DSI in the apical 
4-chamber view. (H) By tracking a speckle from frame-to-frame, myocardial motion 
was assessed and total lateral displacement was determined. (I ) Systolic tissue 
velocity determined by 2DSI. Modified from Knegt et al Eur Heart J Cardiovasc 
Imaging. 2014;15:62–69. 
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